Vaccines, Vol. 8, Pages 689: Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC

alkiviadis.1961 shared this article with you from Inoreader Vaccines, Vol. 8, Pages 689: Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC Via Vaccines Vaccines, Vol. 8, Pages 689: Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC Vaccines doi: 10.3390/vaccines8040689 Authors: Shushan Harutyunyan Irene Neuhauser Alexandra Mayer Michael Aichinger Valéria Szijártó Gábor Nagy Eszter Nagy Petra Girardi Frank J. Malinoski Tamás Henics Shigella spp. and enterotoxigenic Escherichia coli (ETEC) remain the two leading bacterial causes of diarrheal diseases worldwide. Attempts to develop preventive vaccines against Shigella and ETEC have not yet been successful. The major challenge for a broad Shigella vaccine is the serotype-specific immune response to the otherwise protective LPS O-antigen. ETEC vaccines mainly rely on the heat-labile enterotoxin (LT), while heat-stable toxin (ST) has also been shown to be an important virulence factor. Methods: We constructed a combined Shigella and ETEC vaccine (ShigETEC) based on a live attenuated Shigella strain rendered rough and non-invasive with heterologous expression of two ETEC antigens, LTB and a detoxified version of ST (STN12S). This new vaccine strain was characterized and tested for immunogenicity in relevant animal models. Results: Immunization with ShigETEC resulted in serotype independent protection in the mouse lung shigellosis model and induced high titer IgG and IgA antibodies against bacterial lysates, and anti-ETEC toxin antibodies with neutralizing capacity. Conclusions: ShigETEC is a promising oral vaccine candidate against Shigella and ETEC infections and currently in Phase 1 testing. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.